These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36896924)

  • 1. Carcinoid syndrome and somatostatin analogues.
    Varas Lorenzo M
    Rev Esp Enferm Dig; 2023 Dec; 115(12):726-727. PubMed ID: 36896924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
    Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
    Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analogs of somatostatin and carcinoid tumors].
    Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
    Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
    Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
    Rohaizak M; Farndon JR
    ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.
    Wiedenmann B; Räth U; Rädsch R; Becker F; Kommerell B
    Klin Wochenschr; 1988 Jan; 66(2):75-7. PubMed ID: 2894481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin Analogues in Neuroendocrine Tumors.
    Kulke MH
    J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
    [No Abstract]   [Full Text] [Related]  

  • 13. Carcinoid tumours and the role of Sandostatin.
    Woods HF
    NATNEWS; 1989 Jul; 26(7):13-5. PubMed ID: 2779638
    [No Abstract]   [Full Text] [Related]  

  • 14. Somatostatin analogues do not prevent carcinoid crisis.
    Guo LJ; Tang CW
    Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
    Ranft K; Eibl-Eibesfeldt B
    Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
    Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
    Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoid crisis induced by repeated abdominal examination.
    Morrisroe K; Sim IW; McLachlan K; Inder WJ
    Intern Med J; 2012 Mar; 42(3):342-4. PubMed ID: 22432991
    [No Abstract]   [Full Text] [Related]  

  • 20. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.